Anvisa will decide on Wednesday (16) whether pharmacies will be required to retain medical revenues at the time of purchase of medicines such as Ozempic, Wegovy, Saxenda and the like.
Currently, the consumer is already required to show the medical order to the pharmacist at the time of purchase. The discussion, which can define the new rule, began a month ago.
Organ directors should discuss criteria for prescription, control, packaging and labeling of substances based on substances classified as antimicrobials of use under prescription, isolated or in association, as mentioned above.
If the proposal is approved, pharmacies should have revenues.
Data from Anvisa herself point out that 32% of adverse cases notifications in Brazil involve the use of these drugs not indicated in a package insert. The index is more than triple from the global average, which is 10%.
This content was originally published in Anvisa intends to make it difficult for Ozepic on the CNN Brazil website.
Source: CNN Brasil
I’m James Harper, a highly experienced and accomplished news writer for World Stock Market. I have been writing in the Politics section of the website for over five years, providing readers with up-to-date and insightful information about current events in politics. My work is widely read and respected by many industry professionals as well as laymen.
